Hormonal and Biochemical Characteristic of Patients with Ischemic Heart Disease and Adult Growth Hormone Deficiency

In this article the authors analyzed the results of examination of 21 adult patients with ischemic heart disease against adult growth hormone deficiency. The decreasing of mean levels of growth hormone, LH in men and FSH in women in the first group of patients, and in the second group — decrease of mean levels of growth hormone, IGF-1, LH in men and FSH in women indicates the hypopituitarism in both groups of patients, as well as trend to the development of secondary hypogonadism in men. In patients of first and second groups we found increasing of the levels of total cholesterol, VLDL, atherogenic index (p < 0.05), more significant rise of mean levels of triglycerides (p < 0.01), at that more significant disorders of lipid and carbohydrate metabolism were detected in patients of second group. Average levels of LDL, HDL, conjugated bilirubin, urea, blood creatinine and fasting glycemia were also increased

Comparison of microbiota and allergen profile in house dust from homes of allergic and non-allergic subjects- results from the GUSTO study 11 Medical and Health Sciences 1107 Immunology 11 Medical and Health Sciences 1117 Public Health and Health Services

10.1186/s40413-018-0212-5World Allergy Organization Journal111article number 37GUSTO (Growing up towards Healthy Outcomes

Household environmental microbiota influences early-life eczema development

10.1111/1462-2920.15684Environmental MicrobiologyENMI

ScreenPro FH - Screening project for familial hypercholesterolemia in central, southern and eastern Europe: Rationale and design

PubMed ID: 28225290Familial hypercholesterolemia (FH) is a genetic disorder with well-known genetic transmission and clinical course. Despite great recent progress, FH is still underestimated, under-diagnosed and thus undertreated. Furthermore it represents a significant healthcare challenge as a common risk factor for the premature development of coronary heart disease. The ScreenPro FH Project is an international network project aiming at improving complex care - from timely screening, through diagnosis to up-to-date treatment of familial hypercholesterolemia in Central, Eastern and Southern Europe. An important task for the project is to harmonise and unify diagnostic and therapeutic approaches in participating countries, where the situation differs from country to country. Countries with more experience should serve as a model for countries developing the FH network

Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)

Background and aims: Management of familial hypercholesterolaemia (FH) may vary across different settings due to factors related to population characteristics, practice, resources and/or policies. We conducted a survey among the worldwide network of EAS FHSC Lead Investigators to provide an overview of FH status in different countries. Methods: Lead Investigators from countries formally involved in the EAS FHSC by mid-May 2018 were invited to provide a brief report on FH status in their countries, including available information, programmes, initiatives, and management. Results: 63 countries provided reports. Data on FH prevalence are lacking in most countries. Where available, data tend to align with recent estimates, suggesting a higher frequency than that traditionally considered. Low rates of FH detection are reported across all regions. National registries and education programmes to improve FH awareness/knowledge are a recognised priority, but funding is often lacking. In most countries, diagnosis primarily relies on the Dutch Lipid Clinics Network criteria. Although available in many countries, genetic testing is not widely implemented (frequent cost issues). There are only a few national official government programmes for FH. Under-treatment is an issue. FH therapy is not universally reimbursed. PCSK9-inhibitors are available in ∼2/3 countries. Lipoprotein-apheresis is offered in ∼60 countries, although access is limited. Conclusions: FH is a recognised public health concern. Management varies widely across countries, with overall suboptimal identification and under-treatment. Efforts and initiatives to improve FH knowledge and management are underway, including development of national registries, but support, particularly from health authorities, and better funding are greatly needed. © 2018 Elsevier B.V